Anti-tumor Effect and Mechanisms of Hederin： A Review / 中国实验方剂学杂志

ABSTRACT

Hederin is a natural active component of triterpenoid saponins extracted from many medicinal herbs， such as Lithospermum erythrorhizon， Pulsatilla chinensis， and Clematis florida. It has attracted much attention from doctors for its anti-inflammatory， anti-convulsive， anti-oxidation and anti-leishmaniasis activities. Hederin has significant anti-tumor bioactivity and is expected to be a potential drug for the treatment of malignant tumors. The available studies have demonstrated that hederin can promote the apoptosis， inhibit the proliferation， metastasis， and invasion， and induce the autophagy of tumor cells， exhibiting a promising prospect in the treatment of breast cancer， lung cancer， liver cancer， and pancreatic cancer. Specifically， hederin can regulate the phosphoinositide 3-kinase/protein kinase B （PI3K/Akt） pathway， reactive oxygen species （ROS）， and microRNA （miRNA） to trigger tumor cell apoptosis. Its anti-proliferation activity is mainly reflected in the regulation of cyclin and cyclin-dependent kinase （CDK）. Hederin inhibits the metastasis and invasion of tumor cells by blocking epithelial-mesenchymal transformation （EMT）. In addition， hederin can influence metabolic reprogramming to induce tumor cell autophagy. Hederin is involved in a variety of pathways to exert its anti-tumor activity and may become a novel anti-tumor drug in the future， which give new sights into the study of hederin in the anti-tumor field. There are few studies about hederin and no systematic review of its anti-tumor mechanisms. Therefore， this study reviewed the studies about the anti-tumor mechanism of hederin， aiming to provide reference and information for researchers and clinical staff.